Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Human immunodeficiency virus 1 | Integrase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | hypothetical protein | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Plasmodium yoelii | integrase-related | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma brucei | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma congolense | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0589 | 1 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0589 | 1 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0589 | 1 | 0.5 |
Trypanosoma brucei | RNA helicase, putative | 0.0125 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0589 | 1 | 0.5 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0589 | 1 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0589 | 1 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.0589 | 1 | 0.5 |
Loa Loa (eye worm) | carboxylesterase | 0.0589 | 1 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0589 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0589 | 1 | 0.5 |
Echinococcus granulosus | carboxylesterase 5A | 0.0589 | 1 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0589 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AUC (ADMET) | = 2.3 uM.hr | AUC in Sprague-Dawley rat at 2.4 mg/kg, po | ChEMBL. | 17824681 |
CIC95 (functional) | < 0.08 uM | Antiviral activity against HIV13b in MT4 cells assessed as decrease in HIV1 p24 core antigen in presence of fetal bovine serum | ChEMBL. | 17824681 |
CIC95 (functional) | = 0.31 uM | Antiviral activity against HIV1 3b in MT4 cells assessed as decrease in HIV11 p24 core antigen in presence of normal human serum | ChEMBL. | 17824681 |
CL (ADMET) | = 28 ml/min.kg | Plasma clearance in Sprague-Dawley rat | ChEMBL. | 17824681 |
F (ADMET) | = 75 % | Oral bioavailability in Sprague-Dawley rat | ChEMBL. | 17824681 |
IC50 (binding) | = 130 nM | Inhibition of HIV integrase activity by HIV strand transfer assay | ChEMBL. | 17824681 |
IC50 (binding) | = 130 nM | Inhibition of HIV integrase activity by HIV strand transfer assay | ChEMBL. | 17824681 |
Log D | = 2.2 | Distribution coefficient, log D of the compound | ChEMBL. | 17824681 |
PPB (ADMET) | = 93 % | Protein binding in Sprague-Dawley rat plasma | ChEMBL. | 17824681 |
PPB (ADMET) | = 95 % | Protein binding in human plasma | ChEMBL. | 17824681 |
t1/2 (ADMET) | = 2.3 hr | Plasma half life in iv dosed Sprague-Dawley rat | ChEMBL. | 17824681 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.